Belgian Biotech Seed Investment to Produce Affordable Vaccines for Developing Countries

27/10/2015 - 2 minutes

The Belgian biomanufacturing company Univercells and the Japanese pharmaceutical company Takeda have signed a strategic partnership agreement.

Picture4Univercells has closed a €3M equity investment with Takeda Ventures to produce affordable vaccines. Univercells provides single-use cost-efficient bioprocess solutions to lead the next generation in biomanufacturing. Under the terms of the agreement, the two biotechs will launch a development program to tailor Univercells’ continuous integrated manufacturing methods, and applying them to the Takeda vaccines production platform.

Hugues BultotPartnering with Takeda is a strong sign that we are heading in the right direction. We are excited to collaborate with a pioneering global player focused on helping people above all else,” said Hugues Bultot, CEO of Univercells.

jose castillo “Equal access to health around the globe is critical and we believe this comes through decentralized production, which is the biggest challenge in this new era of biomanufacturing” said Jose Castillo, CTO of Univercells.

Meeting global demand is an ongoing challenge for vaccine producers.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member